(Q34449008)

2 August 2017

1 reference

title

Pharmacotherapy of social anxiety disorder at the turn of the millennium (English)

1 reference

2 August 2017

0 references

social anxiety disorder

1 reference

Van Ameringen M

1

1 reference

PubMed ID

11723633

2 August 2017

Mancini C

series ordinal

2

1 reference

2 August 2017

1 December 2001

1 reference

Psychiatric Clinics of North America

2 August 2017

1 reference

2 August 2017

24

1 reference

2 August 2017

783-803

1 reference

2 August 2017

4

1 reference

Paroxetine in social anxiety disorder: a randomized placebo-controlled study

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

The assessment and treatment of performance anxiety in musicians

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Discontinuation of clonazepam in the treatment of social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Bupropion-SR in treatment of social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

The treatment of social phobia. Real-life rehearsal with nonprofessional therapists.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Primary prevention of secondary disorders: a proposal and agenda

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

1 reference

7 January 2021

Social phobia. Review of a neglected anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Citalopram in the treatment of social phobia: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Social phobia. Comorbidity and morbidity in an epidemiologic sample

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Fluoxetine treatment of social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Nefazodone in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Treatment of social phobia with the dopamine agonist pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Nefazodone for social phobia: a clinical case series

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

Social phobia: a comparison of behavior therapy and atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970263-X

7 January 2021

10.1016/S0193-953X(05)70263-X

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11723633